Celon Pharma SA (CLN) Stock Price & News

CLN:WSE

Celon Pharma SA

PLN 19.50

-2.11%

(-0.42) 1D

Sep 28, 5:00:01 PM GMT+2 · PLN

All symbols

YTD

MAX

	Symbol	Price	Change	% Change

Last report

Sep 16, 2026

Fiscal period

Q2 2026

EPS / Est. (PLN)

- / -

Revenue / Est. (PLN)

60.09M / 60.50M

Fiscal Q2 2026 earnings call

Waiting for the earnings call

At a glance

Insights from the latest news and reports

Previous reportsAll values in PLN

Loading Previous Earnings...

All values in PLN	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	55.82M	71.13M	66.67M	61.29M
Cost of goods sold	20.26M	16.83M	11.54M	16.70M
Cost of revenue	20.26M	16.83M	11.54M	16.70M
Research and development expenses	-	-	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	35.01M	33.02M	35.44M	36.08M
Operating expense	52.22M	46.24M	52.60M	50.56M
Total operating expenses	72.48M	63.07M	64.14M	67.26M
Operating income	-16.67M	8.06M	2.53M	-5.98M
Other non operating income	-	-30.00K	-250.00K	169.12M
EBT including unusual items	-26.84M	-2.77M	-6.57M	160.34M
EBT excluding unusual items	-26.84M	-2.77M	-6.57M	160.34M
Income tax expense	5.92M	-6.43M	18.33M	-2.26M
Effective tax rate	-22.05%	232.29%	-279.14%	-1.41%
Other operating expenses	5.98M	2.20M	6.37M	3.36M
Net income	-32.76M	3.66M	-24.90M	162.60M
Net profit margin	-58.70%	5.15%	-37.35%	265.30%
Earnings per share	-	-	-	-
Interest and investment income	550.00K	-	149.00K	151.00K
Interest expense	-304.00K	-	-341.00K	-497.00K
Net interest expenses	246.00K	-	-192.00K	-346.00K
Depreciation and amortization charges	11.23M	11.01M	10.78M	11.13M
EBITDA	-8.28M	16.34M	11.40M	3.44M
Gain or loss from assets sale	2.53M	-170.00K	-2.91M	-569.00K

Finance